Starsource Multitrade

Starsource Multitrade EBIT Growth

The Year-over-Year EBIT Growth of Starsource Multitrade (506365.BO) as of Oct 20, 2026 is 95.57 %. In the previous year, Year-over-Year EBIT Growth was 37.42 % — a change of 155.41% (higher).

EBIT Growth

95.57 %

YoY

155.41%

Last updated:

Year-over-Year EBIT Growth of Starsource Multitrade is 2026 95.57 % . Year-over-Year EBIT Growth of Starsource Multitrade was 2025 37.42 % . It decreases by 155.41% higher compared to the previous year.

The Starsource Multitrade EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-77.08 INR
Jan 1, 2020
18.02 INR
Jan 1, 2021
65.45 INR
Jan 1, 2022
-163.67 INR
Jan 1, 2023
47.63 INR
Jan 1, 2024
12.31 INR
Jan 1, 2025
37.42 INR
Jan 1, 2026
95.57 INR
The Starsource Multitrade EBIT Growth history
YEAREBIT GrowthYoY
95.57 %+155.41%
37.42 %+204.05%
12.31 %-74.16%
47.63 %-129.10%
-163.67 %-350.09%
65.45 %+263.17%
18.02 %-123.38%
-77.08 %+43.67%
-53.65 %-67.57%
-165.45 %+674.93%
-21.35 %-172.80%
29.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Starsource Multitrade Stock analysis

What does Starsource Multitrade do? Starsource Multitrade Ltd focuses on acquiring power and chemicals businesses, having transitioned from its former role as a pharmaceutical company. The company is exploring new business opportunities in the power and chemicals sectors, aiming to expand its portfolio through strategic acquisitions. Chemo Pharma Laboratories Ltd, which was formerly a pharmaceutical company, is now part of this strategic shift, though it has no current operations. The firm targets opportunities in power and chemicals to build its business model. The company's primary revenue stream comes from acquiring and developing power and chemicals businesses, with Chemo Pharma Laboratories Ltd serving as a former entity that has shifted focus. It does not currently operate any pharmaceutical business, instead concentrating on power and chemicals acquisitions. The business model relies on identifying and integrating new acquisitions in the power and chemicals sectors to generate revenue. Starsource Multitrade Ltd is actively seeking to acquire businesses in the power and chemicals sectors, having moved away from its pharmaceutical roots. The firm has no current operations, indicating a focus on future acquisitions rather than existing business activities. Chemo Pharma Laboratories Ltd, once a pharmaceutical company, is now part of the company's strategic repositioning towards power and chemicals. Starsource Multitrade is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Starsource Multitrade stock

Year-over-Year EBIT Growth of Starsource Multitrade is 95.57 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Starsource Multitrade since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Starsource Multitrade historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Starsource Multitrade

All Key Metrics — Starsource Multitrade